In the first phase of this collaboration, the companies will test the feasibility of smart patch-based transdermal delivery of a peptide drug candidate in animal models.
Upon completion of this study, the companies could decide to further develop and commercialize this peptide or other peptide therapeutics in Zealand Pharma’s product portfolio.
Haro Hartounian, president and CEO of Vyteris, said: “This strategic partnership with Zealand Pharma, a recognized leader in peptide drug development, marks another milestone in the active roll-out of our patented smart patch transdermal technology for the delivery of high-value, therapeutic peptides.”